| 02.16.22 | Roche posts 2-year data on eye implant; Yale spinout plans nasal COVID-19 vaccine

Click here to subscribe to Fiercebiotech.com

2 years ago

Html
Text

Case Study: Versatility of Softgel Technology – Encapsulation of a Volatile Compound

Discover how Catalent supported a company to develop softgels featuring a special shell to release quickly and prevent evaporative loss during and after manufacturing. Download now.

Today's Rundown

Roche’s eye implant retains efficacy, schedule out to two years Xanadu spins out of Yale with nasal COVID-19 vaccine tech, teeing up push to curb viral transmission Opiant's nasal opioid overdose drug clears PK test, edges closer to FDA filing NIH-backed nasal nonaddictive pain prospect clears early test The top 10 M&A targets in biotech for 2022

Featured Story

Roche’s eye implant retains efficacy, schedule out to two years

By Nick Paul Taylor

Roche is building the case for its vision loss implant Susvimo. The latest update shows 95% of patients on Susvimo maintained a six-month treatment schedule after two years, giving Roche another data point to use as it seeks to gain a slice of the wet age-related macular degeneration (AMD) market.

This week's sponsor is CPC.

Xanadu spins out of Yale with nasal COVID-19 vaccine tech, teeing up push to curb viral transmission

By Nick Paul Taylor

Xanadu Bio has spun out of Yale University with a nanoparticle delivery platform, positioning it to work on COVID-19 booster vaccines that could be more effective at stopping viral infection and transmission than existing products are.

Opiant's nasal opioid overdose drug clears PK test, edges closer to FDA filing

By Nick Paul Taylor

Opiant Pharmaceuticals has taken another step toward filing for approval of its nasal opioid overdose drug. With the pharmacokinetic study showing the drug is absorbed quickly in the nose, Opiant remains on track to submit an application to the FDA later this year.

NIH-backed nasal nonaddictive pain prospect clears early test

By Nick Paul Taylor

Virpax Pharmaceuticals has brought its nasal spray for acute and chronic pain through an early test. With the NIH footing the bill, Virpax posted a clear toxicology report in a preclinical studies in preparation for filing to study the candidate in humans.

The top 10 M&A targets in biotech for 2022

By Annalee Armstrong

All the biopharma world is talking about right now is M&A. Who’s going to buy? How much are they willing to spend? Who’s going to get bought? Here are our predictions.

Webinar: Strategies to Optimize the Dosage Form Design Process to Create Better Treatments

Watch this webinar to hear from experts as they use case studies to demonstrate how the right guidance, at the right time, can help drug developers create better treatments. Register now.